Although TMB is thought to predict the response to PD-1/PD-L1 blockade in NSCLC patients, TMB needs to be accurately calculated by whole exome sequencing (WES), a method that is expensive and unaffordable for most patients [15]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.